AZ’ Lynparza cuts risk of breast cancer progression
admin 5th June 2017 Uncategorised 0AstraZeneca has unveiled new data showing a significant reduction in the risk of death or disease progression in certain patients with breast cancer taking its PARP inhibitor Lynparza.
More: AZ’ Lynparza cuts risk of breast cancer progression
Source: News